




Portfolio Overview - Versant Ventures

































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 








PARTNERING TO IMPROVE HEALTHCARE


We are proud of our track record of working with extraordinary scientists, entrepreneurs and business leaders to build transformational companies that impact and improve healthcare.
We invest our time, talent, leadership and expertise in all our portfolio partnerships. We pursue opportunities where we can add value through our hands-on collaborative approach, and devote the appropriate mix of strategic advice, domain expertise and capital to help accelerate their growth.
We invest in life and in success. Since our inception in 1999, we have invested in over 125 seed, early and growth stage companies – of which 65 have gone public or been acquired to date.
 























Contact Us - Versant Ventures
































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 








CONTACT US AT ONE OF OUR FIVE OFFICES


San Francisco


One Sansome, Suite 3630 San Francisco, CA 94104

																					Phone: (415) 801-8100																																									Fax: (415) 801-8101																			







New York


54 West 21st Street Suite 408 New York, NY 10010

																					Phone: (646) 357-1286																																							







Minneapolis


7800 Equitable Drive Suite 150 Eden Prairie, MN 55344

																					Phone: (612) 254-1170																																							







Basel, SWITZERLAND


Versant Ventures (Switzerland) GmbH
Aeschenvorstadt 36 CH-4051 Basel, Switzerland

																					Phone: +41 61 225 46 00																																							







Canada


Versant Ventures Canada Limited
887 Great Northern Way Suite 210 Vancouver, BC V5T 4T5

																					Phone: (604) 424-9913																																							































Medical Devices Archives - Versant Ventures






























Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 







Medical Devices




   

				Ebb Therapeutics			 
Oakmont, PA


Ebb is developing a therapeutic device for insomnia.
 
 


   

				Inari Medical			 
Irvine, CA


Inari Medical is a medical device company pioneering innovative devices for the interventional treatment of vascular thrombi and emboli.
 
 


   

				Metavention			 
Minneapolis, MN


Metavention is developing novel interventional therapies for type 2 diabetes.
 
 


 

							Sebacia					
Duluth, GA


Sebacia is developing a medical device to cure acne.
 
 


   

				Zyga Technology			 
Minneapolis, MN


Zyga is developing and marketing innovative, minimally invasive surgical solutions to treat conditions of the spine.
 
 


   

				Rox Medical			 
San Clemente, CA


Rox is developing devices for treatment of diseases of the respiratory system.
 
 


   

				Respicardia			 
Minnetonka, MN


Respicardia is developing an implantable system to treat central sleep apnea in patients with heart failure.
 
 


   

				OraMetrix			 
Richardson, TX


OraMetrix is a leading industry provider of innovative 3-D technology solutions facilitating and improving the quality of orthodontic care.
 
 


   

				Neurotech Pharmaceuticals			 
Lincoln, RI


Neurotech Pharmaceuticals is pioneering encapsulated cell technology as a drug delivery platform for retinal degenerative diseases.
 
 


   

				Minerva Surgical			 
Cupertino, CA


Minerva is developing next–generation technology for treating excessive menstrual bleeding.
 
 


   

				Microfabrica			 
Van Nuys, CA


Microfabrica has developed a broad micro-scale platform for minimally invasive procedures and for complex dynamic implants.
 
 


   

				Intuity Medical			 
Sunnyvale, CA


Intuity Medical, formerly Rosedale, is developing a handheld, all in-one discrete, blood-based diagnostic platform that will enhance glucose monitoring for diabetic patients.
 
 


   

				Holaira			 
Plymouth, MN


Novel devices to treat obstructive lung disease.  Previously, Innovative Pulmonary Solutions.
 
 


   

				Halscion			 
Suwanee, GA


Halscion is advancing a solution for reduction of surgically induced scarring.
 
 


   

				ForSight Vision 4			 
Menlo Park, CA


ForSight VISION4 is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets.
 
 


   

				ForSight Vision 5			 
Menlo Park, CA


ForSight Vision 5, Inc. is developing novel ocular drug delivery technologies.
 
 


   

				Ceterix Orthopedics (fka SuturePro Technologies, Inc.)			 
Menlo Park, CA


Ceterix is developing a new orthopedic suturing technology that is focused on improving ease-of-use and operative speed.
 
 


   

				Celula			 
San Diego, CA


Celula is developing rare cell isolation technology for diagnostic and therapeutic purposes.
 
 


   

				Benvenue Medical			 
Santa Clara, CA


Benvenue Medical is developing and marketing innovative spine repair technology.
 
 


   

				AlterG			 
Fremont, CA


AlterG is marketing its “G-Trainer” technology, a treadmill system that reduces the users’ body weight/impact of running and thereby enhances physical rehabilitation from orthopedic or neurological injury.
 
 


   

				AcuFocus			 
Irvine, CA


AcuFocus is developing a corneal implant to treat presbyopia (the need for reading glasses).
 
 


Portfolio CompaniesBiotechnology
Biotechnology Exits & IPOs
Medical Devices
Medical Device Exits & IPOs
Additional Investments
Additional Investment Exits
Discovery Engines
  Case Studies 
Amira Pharmaceuticals
Inception 3, Inc.
Quanticel Pharmaceuticals






















Biotechnology Archives - Versant Ventures






























Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 







Biotechnology




   

				VenatoRx Pharmaceuticals			 
Malvern, PA


VenatoRx is a developing next-generation antibiotics to treat multi-drug resistant (MDR) infections.
 
 


   

				Vividion Therapeutics			 
San Diego, CA


Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery.
 
 


   

				Repare Therapeutics			 
Montreal, Canada


Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
 
 


   

				Northern Biologics			 
Toronto, Canada


Northern Biologics is developing novel therapeutic antibodies for the treatment of human diseases in oncology, fibrosis, and other diseases. 
 
 


   

				PIQUR Therapeutics			 
Basel, Switzerland


PIQUR is a Swiss pharmaceutical company focusing on the discovery and development of innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibition for the treatment of cancer as well as other indications.
 
 


   

				Anokion			 
Ecublens, Switzerland


Anokion is focused on leveraging its proprietary immune tolerance technology to develop novel protein therapeutics and treatments for autoimmune diseases.
 
 


   

				Mosaic Biomedicals			 
Barcelona, Spain


Mosaic Biomedicals is a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor’s immune system. Mosaic’s innovative treatments are derived from a deep understanding of the tumor biology and aim to offer safer and more effective options to cancer patients.
 
 


   

				AAVLife			 
Paris, France


AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.
 
 


 

							Inception IBD					
San Diego, CA


Inception IBD is focused on translating academic discoveries in the field of IBD into first-in-class small molecule drugs.
 
 


   

				CRISPR Therapeutics			 
Basel, Switzerland


CRISPR Therapeutics is making use of significant advances in the field of gene editing and focused on translating the CRISPR-Cas9 technology in truly transformational therapeutics for common and rare genetic diseases.
 
 


   

				Audentes Therapeutics			 
San Francisco, CA


Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
 
 


   

				Gensight Biologics			 
Tassin la Demi Lune,  69160 France


GenSight is a leading company in gene therapy specialized in prevention of loss of vision and restoration of sight.
 
 


   

				Inception 3			 
San Diego, CA


Inception 3 is focused on the discovery of therapeutics for sensorineural hearing loss.  The company has entered into a partnership with Roche with a pre-negotiated acquisition at IND.
 
 


   

				Viral Logic Systems Technology			 
Seattle, WA


VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases.
 
 


   

				Theraclone Sciences			 
Seattle, WA


Theraclone Sciences, Inc. is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases.
 
 


 

							Acumen					
San Francisco, CA


Acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphone-enabled digital behavior evaluation, improving outcomes for patients and simplifying care for specialists.
 
 


   

				PhaseRx			 
Seattle, WA


PhaseRx is developing a novel approach to intracellular delivery of macromolecules.
 
 


   

				Inception 2			 
San Diego, CA


Inception 2 is focused on Oncology. The company is translating biological insights into novel, first-in-class small molecule drugs for CLL and other oncology indications spanning both liquid and solid tumors.
 
 


   

				Inception 1			 
San Diego, CA


Inception 1 is translating biological insights into novel, first-in-class, small molecule drugs to treat diseases of aging.
 
 


   

				RuiYi			 
Shanghai, China


RuiYi is a drug discovery and development company focused on first-in-class antibodies targeting G protein coupled receptors (GPCRs).
 
 


   

				5AM Ventures			 
Menlo Park, CA


5AM Ventures is a seed-stage fund focused on creating and building biotech companies.
 
 


Portfolio CompaniesBiotechnology
Biotechnology Exits & IPOs
Medical Devices
Medical Device Exits & IPOs
Additional Investments
Additional Investment Exits
Discovery Engines
  Case Studies 
Amira Pharmaceuticals
Inception 3, Inc.
Quanticel Pharmaceuticals






















Versant Overview - Versant Ventures

































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 








PROPELLING LIFE SCIENCES COMPANIES


Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.
Versant in Europe
Versant Ventures has a team in Basel, Switzerland, dedicated to working with entrepreneurs, industry and leading academics across Europe. The team has decades of experience in the pharmaceutical and biotechnology industries, including global roles in drug discovery, research and product development for companies such as Roche, Novartis and Lilly. Versant’s Basel office is led by Tom Woiwode, Guido Magni and Gianni Gromo.
 
 























Versant Overview - Versant Ventures

































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers










 








PROPELLING LIFE SCIENCES COMPANIES


Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.
Versant in Europe
Versant Ventures has a team in Basel, Switzerland, dedicated to working with entrepreneurs, industry and leading academics across Europe. The team has decades of experience in the pharmaceutical and biotechnology industries, including global roles in drug discovery, research and product development for companies such as Roche, Novartis and Lilly. Versant’s Basel office is led by Tom Woiwode, Guido Magni and Gianni Gromo.
 
 























Home - Versant Ventures


































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers














I've built two companies with Versant Ventures and value their distinctive investment approach. They have a clear understanding of the recipe for start-up company success and represent a premium brand in healthcare venture capital today.
David Clapper
 / Minerva Surgical
Versant. Invested in Life.





The people at Versant understand the entrepreneurial process. They take a long-term view of the portfolio company, and help provide perspective and support in times thick and thin.
Amar Sawhney
 / Ocular Therapeutix
Versant. Invested in Life.





Versant has been and continues to be a superb investor. They provide insight and counsel to our efforts and their willingness to roll up their sleeves to problem solve with us has been invaluable.
Michael D. Clayman, MD
 / Flexion Therapeutics
Versant. Invested in Life.











 


Featured Case Study




BIOTECHNOLOGY
Quanticel Pharmaceuticals
Quanticel technology is based on the work of Stanford researchers and company founders Stephen Quake and Michael Clarke. Versant had backed other genomic technologies invented by Quake, and moved quickly to incubate Quanticel in 2010, shortly after the company was founded.

The idea behind Quanticel’s single-cell genomic analysis technology is to unlock the mystery of cancer drug resistance through the analysis of tumor cell heterogeneity. As a tumor grows and cancer cells rapidly replicate, the genetic diversity of these cells increases...
Full Quanticel Pharmaceuticals Case Study








News Highlights

VenatoRx Pharmaceuticals Raises $42 Million Series B 
VenatoRxfinal 


Repare Therapeutics Raises $US68 Million Series A 
Repare Therapeutics Raises US$68 Million Series A 


CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation 
CRISPR appoints Jon Terrett 


Versant Ventures Launches Jecure Therapeutics 
jecure-series-a 




















Versant Ventures - Office in Sharon Height


FoursquareLog InSign UpNearby:Get inspired:Top PicksTrendingFoodCoffeeNightlifeFunShoppingVersant VenturesOfficeSharon Height, Menlo ParkSaveShareTipsPhotos 1Versant VenturesNo tips and reviewsLog in to leave a tip here.PostNo tips yetWrite a short note about what you liked, what to order, or other helpful advice for visitors.1 PhotoRelated Searchesversant ventures menlo park  versant ventures menlo park photos  versant ventures menlo park location  versant ventures menlo park address  versant ventures menlo park  versant ventures menlo park  versant ventures sharon height menlo parkAboutBlogBusinessesCitiesDevelopersHelpJobsCookies (Updated)Privacy (Updated)TermsEnglishEnglish Français Deutsch Bahasa Indonesia Italiano 日本語 한국어 Português Русский Español ภาษาไทย Türkçe Cities:AtlantaAustinBostonChicagoDallasDenverHoustonLas VegasLos AngelesNew YorkPhiladelphiaPortlandSan DiegoSan FranciscoSeattleWashington, D.C.Countries:BelgiumBrazilCanadaChileFinlandFranceGermanyGreat BritainHungaryIndonesiaJapanMexicoNetherlandsPhilippinesRussiaSingaporeSpainThailandTurkeyMore Great Places in Menlo Park:abcdefghijklmnopqrstuvwxyz#Foursquare © 2017  Lovingly made in NYC & SFVersant Ventures3000 Sand Hill RdMenlo Park, CA 94025United StatesGet directions See MoreUnited States » San Mateo County » Menlo Park » Sharon HeightIs this your business? Claim it now.Make sure your information is up to date. Plus use our free tools to find new customers.You must enable JavaScript to use foursquare.comWe use the latest and greatest technology available to provide the best possible web experience.Please enable JavaScript in your browser settings to continue.Download Foursquare for your smart phone and start exploring the world around you!

Versant Venture Management, LLC: Private Company Information - Bloomberg









































  





















































































July 29, 2017 12:27 AM ET
Capital Markets

Company Overview of Versant Venture Management, LLC



Snapshot People




Company Overview
Versant Venture Management, LLC is a venture capital and private equity firm specializing in incubation, seed, start-ups, growth stage, early stage and later stage investments. It seeks to invest in all segments of healthcare including discovery and development of novel therapeutics; medical devices and diagnostics; med-tech; life sciences that include biopharmaceuticals and biotechnology platforms; healthcare services; healthcare information technology, industry specific software  and healthcare industry software. The firm prefers to invest in companies based in the United States and Western Europe. The firm seeks to invest in the biotechnology sector in Canada. The firm typically invests b...
Versant Venture Management, LLC is a venture capital and private equity firm specializing in incubation, seed, start-ups, growth stage, early stage and later stage investments. It seeks to invest in all segments of healthcare including discovery and development of novel therapeutics; medical devices and diagnostics; med-tech; life sciences that include biopharmaceuticals and biotechnology platforms; healthcare services; healthcare information technology, industry specific software  and healthcare industry software. The firm prefers to invest in companies based in the United States and Western Europe. The firm seeks to invest in the biotechnology sector in Canada. The firm typically invests between $10 million and $20 million into each startup before it’s sold or goes public. It will not invest in a company unless it has at least $500 million in annualized potential in the United States. The firm also backs companies developing products that must go through the Food and Drug Administration’s premarket approval process (PMA). Versant Ventures was founded in 1999 and is headquartered in San Francisco, California with additional offices in San Diego, California; New York, New York; Eden Prairie Minneapolis; Basel, Switzerland; and Vancouver, Canada.
Detailed Description


One Sansome StreetSuite 3630San Francisco, CA 94104United StatesFounded in 1999



Phone: 415-801-8100

Fax: 415-801-8101

www.versantventures.com







Key Executives for Versant Venture Management, LLC




Ms. Barbara N. Lubash MS


      	Managing Director
      








Mr. Donald B. Milder


      	Managing Director
      


Age: 62
        







Mr. Brian G. Atwood Veracyte


      	Co-founder & MD
      


Age: 64
        







Mr. William J. Link Ph.D.


      	Co-Founder & MD
      


Age: 71
        







Mr. Samuel D. Colella MBA


      	Managing Director
      


Age: 77
        




Compensation as of Fiscal Year 2017. 

Versant Venture Management, LLC Key Developments

Versant Ventures, Inc. Presents at The Medtech Conference, Jun-01-2017
May 30 17
Versant Ventures, Inc. Presents at The Medtech Conference, Jun-01-2017. Venue: The Loews Minneapolis Hotel, 601 1st Ave N, Minneapolis, MN 55403, United States. Presentation Date & Speakers: Jun-01-2017, Kevin Hykes, Operating Partner.


Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics
Dec 12 16
Bayer AG and Versant Ventures announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an platform. BlueRock Therapeutics will be led by a team and has assembled its platform through a series of strategic partnerships with academia and industry. To enable BlueRock Therapeutics' platform and pipeline, Bayer and Versant are committing USD 225 million, representing one of the ever series A financings for a biotech company. The funds are projected to give BlueRock Therapeutics at least four years of runway and will allow the new company to advance a number of programs into the clinic, with an initial focus on cardiovascular diseases and neurodegenerative disorders. BlueRock Therapeutics' platform is enabled by strategic partnerships with a number of leading academic and industry collaborators in the U.S., Canada and Japan.


Versant Ventures, Inc. Presents at NY/NJ CEO Conference, Nov-03-2016 11:45 AM
Oct 29 16
Versant Ventures, Inc. Presents at NY/NJ CEO Conference, Nov-03-2016 11:45 AM. Venue: Apella at Alexandria Center, 450 E. 29 Street, New York, NY 10016, United States. Speakers: Carlo Rizzuto, Partner.


Similar Private Companies By Industry



Company Name
Region



 @Visory LLC United States 1 Road Partners LLC United States 11T Partners, LLC United States 123Jump.com, Inc. United States 1509225 Ontario, Inc. United States




Recent Private Companies Transactions



TypeDate
Target





Private Placement

			      July 25, 2017
			    
Sebacia, Inc.



Private Placement

			      July 13, 2017
			    
VenatoRx Pharmaceuticals, Inc.



Private Placement

			      June 22, 2017
			    
Repare Therapeutics Inc.





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Versant Venture Management, LLC, please visit www.versantventures.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close







































Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.













 




Versant Ventures Management LLC: Company Profile - Bloomberg



































































  









Feedback











































versant ventures management llc
Private Company









Company Profile
Sector: Financials
Industry: Asset Management
Sub-Industry: Private Equity
Versant Venture Management, LLC operates a venture capital firm. The Company invests in medical devices, biotechnology, life science, pharmaceuticals, and healthcare sectors, as well as offers investment management services. Versant Venture Management serves clients worldwide.




Corporate Information
Address:

1 Sansome
Suite 3630
San Francisco, CA 94104
United States


Phone:
1-415-801-8100


Fax:
1-415-801-8101


Web url:
www.versantventures.com





Board Members




Board Members
Company


Robert Grant
Myoscience Inc


























From The Web











Key Executives


Brian G Atwood


Managing Director/Co-Founder




Samuel D Colella "Sam"


Managing Director/Co-Founder




Ross A Jaffe


Managing Director/Co-Founder




William J Link "Bill"


Managing Director/Co-Founder




Barbara N Lubash


Managing Director/Co-Founder




Donald B Milder "Don"


Managing Director/Co-Founder




Rebecca B Robertson "Beckie"


Managing Director/Co-Founder




Robin Praeger


Managing Director/CFO




Kirk Nielsen


Managing Director




Bradley J Bolzon "Brad"


Managing Director




Charles M Warden


Managing Director




Thomas Woiwode "Tom"


Managing Director




Jerel Davis


Managing Director




Clare Ozawa


Managing Director




Gianni Gromo


Partner




Guido Magni


Partner




Carlo Rizzuto


Partner




Alex Mayweg


Venture Partner




Mary Haak-Frendscho


Venture Partner




Kevin Hykes


Operating Partner



Show More


Show Less






Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data














































 





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft

































Second Sight Medical Products (NASDAQ:EYES) Given News Impact Rating of 0.31 - Watch List News



















































Home
About
Staff
Privacy Policy
Contact
























Headlines
Business
US News
Health
World
Investing
Technology




















Second Sight Medical Products Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for Second Sight Medical Products Inc. with our FREE daily email newsletter:



 






Follow Watchlist News

 











Latest News



Advanced Micro Devices, Inc. (NASDAQ:AMD) Announces  Earnings Results					

uniQure N.V. (QURE) Given a $13.00 Price Target by Chardan Capital Analysts					

Endo International PLC (NASDAQ:ENDP) Receives Hold Rating from Oppenheimer Holdings, Inc.					

Northland Securities Analysts Give Viper Energy Partners LP (NASDAQ:VNOM) a $22.00 Price Target					

Wix.com Ltd. (NASDAQ:WIX) Now Covered by KeyCorp					

Centerra Gold Inc. (TSE:CG) Stock Rating Reaffirmed by National Bank Financial					

Tahoe Resources Inc (THO) Stock Rating Reaffirmed by National Bank Financial					

New Gold Inc. (TSE:NGD) Stock Rating Reaffirmed by National Bank Financial					

PPG Industries, Inc. (PPG) Given a $113.00 Price Target by Credit Suisse Group Analysts					

Sherwin-Williams Company (The) (NYSE:SHW) Upgraded to “Buy” by Credit Suisse Group					

New Gold Inc. (NGD) Rating Reiterated by National Bank Financial					

SunTrust Banks, Inc. (STI) Earns Hold Rating from Oppenheimer Holdings, Inc.					

Stifel Nicolaus Reiterates Hold Rating for J.B. Hunt Transport Services, Inc. (JBHT)					

Microsoft Corporation’s (NASDAQ:MSFT) Neutral Rating Reaffirmed at MKM Partners					

Goldcorp Inc. (G) Rating Reiterated by National Bank Financial					

Alamos Gold Inc (AGI) Earns Outperform Market Weight Rating from National Bank Financial					

American Airlines Group, Inc. (NASDAQ:AAL) Given “In-Line” Rating at Imperial Capital					

Plug Power, Inc. (PLUG) Stock Rating Reaffirmed by Roth Capital					

Susquehanna Bancshares Inc Reaffirms Positive Rating for Super Micro Computer, Inc. (SMCI)					

Ironwood Pharmaceuticals, Inc. (IRWD) Earns Outperform Rating from Cowen and Company					



Archives

July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
March 2016
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014




 




						Second Sight Medical Products (NASDAQ:EYES) Given News Impact Rating of 0.31					

						 July 17th, 2017  - 0 comments - Filed Under -
 by Lindsey Winhoffer 


							Filed Under: Investing - News Sentiment Articles 






Tweet










News stories about Second Sight Medical Products (NASDAQ:EYES) have been trending positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near future. 
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis: 

SECOND SIGHT MEDICAL PRODUCTS INC : Other Events (form 8-K) (4-traders.com)
Second Sight Medical Products (EYES) (seekingalpha.com)
Are There Any Catalysts to Propel Second Sight Medical Products … – FLBC News (flbcnews.com)
Is There Strength Behind the Numbers For Second Sight Medical Products Inc (EYES) – FLBC News (flbcnews.com)
Long Term: Second Sight Medical Products, Inc. (EYES) weak Trend – Stocks Gallery (stocksgallery.com)

Shares of Second Sight Medical Products (NASDAQ EYES) opened at 1.31 on Monday. Second Sight Medical Products has a 12 month low of $1.06 and a 12 month high of $4.50. The firm’s 50-day moving average is $1.17 and its 200 day moving average is $1.45. The company’s market capitalization is $73.84 million. 




Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Wednesday, May 3rd. The medical device company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $1.01 million for the quarter, compared to analyst estimates of $1.32 million. Second Sight Medical Products had a negative net margin of 885.84% and a negative return on equity of 147.12%.  Equities research analysts predict that  Second Sight Medical Products will post ($0.52) EPS for the current year. 
Several equities research analysts have commented on the stock. HC Wainwright  reissued a “buy” rating and set a $5.00 price target on shares of Second Sight Medical Products in a research report on Thursday, July 6th. Zacks Investment Research cut shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th.
ILLEGAL ACTIVITY WARNING: “Second Sight Medical Products (NASDAQ:EYES) Given News Impact Rating of 0.31” was originally  reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/second-sight-medical-products-nasdaqeyes-given-news-impact-rating-of-0-31/1444237.html. 
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.



Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.



 










Lindsey Winhoffer 























 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!




Latest News




Sirius XM Making Big Investment In Pandora





Tax Reform Not Going Quite As Planned





Western Digital Files Lawsuit To Halt Toshiba Chip Business Sale





Sinclair Broadcast Group Announces Deal For Tribune Media





Starbucks Has A Hit With Its Unicorn Frappuccino











			© Watch List News, LLC 2008-2017. All rights reserved. 


Privacy Policy |
			About | Staff 
			| Contact 












































Versant Venture Management LLC                                                                                           - San Francisco                                     , CA         - Company Information









 



























Products
Resources
My Account












Talk to a D&B Advisor 
1-800-280-0780 




Business Directory



CA



San Francisco



Investors, Nec



Venture Capital Companies



                            Versant Venture Management LLC
                                    



 





















V 


Versant Venture Management LLC                                                                                          
CLAIM THIS BUSINESS



1 SANSOME ST STE 3630 SAN FRANCISCO, CA 94104
Get Directions



(650) 233-7877
www.versantventures.com                                                                                 





Business Info



 Founded 1999
 Incorporated 
 Annual Revenue $4,736,591.00
 Employee Count 20
 Industries Venture Capital Companies
 Contacts Robin L Praeger                                                                                                         







Contact Business







Your Email Address

Subject:


Message


Send Message





Company Summary


Since 1999, Versant Venture Management Llc                                                                                           has been providing Venture Capital Companies from San Francisco. 









VERIFIED Status:
UNVERIFIED



Address:
UNVERIFIED





LAST VERIFIED:

                                    --
                                



Phone:

                                    UNVERIFIED
                                





Payment Method:
UNVERIFIED


view full report





Similar Businesses Nearby


                                        Our similar businesses nearby shows similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Competitive Landscape


                                        Our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Payments Accepted

NO DATA



Hours



                                        Sunday 

                                        

                                                                                            --
                                            
                                        



                                        Monday 

                                        

                                                                                            --
                                            
                                        



                                        Tuesday 

                                        

                                                                                            --
                                            
                                        



                                        Wednesday 

                                        

                                                                                            --
                                            
                                        



                                        Thursday 

                                        

                                                                                            --
                                            
                                        



                                        Friday 

                                        

                                                                                            --
                                            
                                        



                                        Saturday 

                                        

                                                                                            --
                                            
                                        







V

VIEW ADDITIONAL DATA                        
Select from over 115 networks below to view available data about this business. If this data is unavailable or inaccurate and you own or represent this business, click here for more information on how you may be able to correct it. 







Credibility Review





Google





Facebook.com





Yellowbook.com





Bing.com





Yellowpages.com





MerchantCircle





Tele Atlas (TomTom)





Twitter.com





AOL





MapQuest





Yahoo Local





Apple/Siri





Groupon





Hotfrog.com





Comcast.net Search





ReachLocal





Admedia





Dealsplus





Shoptopia.com





Alteryx





Dogtime Media





KSL.com





Sirtune





AmericanTowns.com





Driverside





Kudzu.com





SpecialsAgent.com





Answers.com





eGood





LawInfo.com





spotlikes.com





anywho.com





eGumball





Likeness.com





Spotzot





eServiceLog





MapMyRun





TechnoCom





apartmentguide.com





ezlocal.com





EZToUse.com





Teleroute





AroundMe.com





metropolist.com





Therapists.com





Atlanta NewHomes





FindLaw.com





Time Out New York





Avantar





FindTheBest.com





mojopages.com





B2B Yellowpages





Fivestar Software





MyCityWay.com





TripAdvisor





bckyrd.com





GiftCards.com





MyCoupons.com





beachcalifornia.com





GoLocal247.com





mymove.com





UpMeSocial.com





Belo





GoodInfo





News-Gazette





Nokia





usdirectory.com





Cars.com





Nomao





Centzy.com





hibu





Openlist.com





ChaCha Search





Homeplate.com





OwnLocal.com





VisiKard





challama.com





Homestore





patch.com





Voltari





CityBot





Pelopidas





Vouchd





ClassifiedAds





Hostway





PlaceIQ





WalkScore.com





CloudMade





Hoodoyou





PlanetDiscover.com





WeddingWire.com





PowerProfiles





Where Inc.





Contractors.com





iGoLocal.com





Radiate Media





Wikiocity





CouponMap





Indeed.com





Wimgo.com





CrowdSpot





Innova Electronics





Intellistrand





realtor.com





DataSphere





InTheMO.com





Reply.com





Yellowbot.com





JiWire





Rocket Fuel





YellowPageCity.com





DMV.org





Justclicklocal.com





Dirxion





Keen.com





Zidster.com












Photos














































Business Credit Report
Receive a one-time comprehensive credit report on this company.
get full credit report


Facebook








Twitter








Yelp






































Call 1.800.280.0780 to speak with a D&B Advisor Today!







Customer Resources
Products
Education Center
Business Articles & Insights
Glossary
Contact Us
Customer Support
Communication Preferences
Search for D&B D-U-N-S




Our Company
About Us
Company History
Business Credit History
Careers
Press Releases
News
Success Stories
Hoovers




Our Network
Partners
Affiliates
Blog
Access to Capital
Entrepreneurial Initiative
D&B International
SupplierEdge




Site Links
Business Directory
Site Map
PIPEDA
Privacy Policy
Website Terms of Service
Product License Agreement







© Dun & Bradstreet, Inc. 2017. All rights reserved.


















Versant Venture Management LLC | Revenue and Financial Reports - D&B Hoovers








































































Menu









Buy Reports & Lists
How It Works




United States
United Kingdom



(855) 891-0791


Login
















Company
People
Industry





Search D&B Hoovers: Company | People | Industry








Login





Avention OneSource is now D&B Hoovers. Login here for access to D&B Hoovers, D&B DataVision, D&B Business Browser and iSell
Login







For customers of Hoovers prior to March 1, 2017.
Login




















Call (866) 473-3932





Chat software by BoldChat



Start Free Trial








Call (866) 473-3932





Chat software by BoldChat



Start Free Trial




















Search the D&B Hoovers Database

Company

Company
People
Industry

















Home
                >Company Information
                >Company Search
                >Company Overview - Revenue & Financial Data

















Company Profile


Information For


Sales Preparation


Marketing Contacts


Competition


Revenue & Financial


Available Products


Company Report


Finance and Insurance Sector Industry Report


Investment Firms Industry Report


Venture Capital Industry Report















Versant Venture Management LLC Revenue and Financial Data

   Versant Venture is conversant in the world of health care startups. Doing business as Versant Ventures, the firm primarily invests in early-state health care and biotech companies including medical device makers, service providers, pharmaceuticals, and IT firms. It targets companies with potential sales of more than $500 million. Versant manages more than $1.6 billion in committed capital in some 75 portfolio firms. Holdings include include Fluidigm, Cogent Healthcare, and Metabolex. A group of managing directors including Samuel Colella co-founded Versant Ventures in 1999.
  







Financials Information for Versant Venture Management LLC

        Track this company’s financial condition.
View Company Report
Request Your Free Trial




Income Statement
Cash FlowBalance SheetCredit Rating







Income Statement (mil)





Revenue
$4.736591 (Estimated)


Gross Profit
$0.0 (Estimated)


Operating Income
$0.0 (Estimated)


Net Income
$0.0 (Estimated)


Diluted EPS
$0.0 (Estimated)










Cash Flow (mil)





Cash at the beginning of the year
$


Net Operating Cash
$


Net Investing Cash
$


Net Financing Cash
$


Net Change in Cash
$


Cash at end of the year
$


Capital Expenditure
$










Assets (mil)





Current Assets


Cash
$


Net Receivables
$


Inventories
$


Other Income Assets
$


Asset Summary


Total Current Assets
$


Net Fixed Assets
$


Other Noncurrent Assets
$


Total Assets
$






Liabilities (mil)





Current Liabilities


Accounts Payable
$


Short Term Debt
$


Other Current Liabilities
$


Liability Summary


Total Current Liabilities
$


Long Term Debt
$


Other Noncurrent Liabilities
$


Total Liabilities
$






Stakeholder's Equity (mil)





Equity


Preferred Stock Equity
$


Common Stock Equity
$


Equity Summary


Total Equity
$


Shares Outstanding








Credit Rating
              
                
                        High
                        These businesses have a high projected rate of delinquency OR a high failure risk. 






 Need to go deeper? No problem.  Save time with complex financial data at your fingertips Access financial statements, SEC filings, earnings estimates, and more Call (866) 473-3932 to talk to a Business Information Consultant    Request Your Free Trial    


































FREE Alerts to Changes in Your D&B® Credit Scores!* Sign Up.
Get CreditSignal® for FREE!*












Try D&B Credit FREE for 30 Days! Get Started.
Try D&B Credit FREE for 30 Days





















 






Brad Bolzon, Managing Director, Versant Venture Management, LLC


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Brad Bolzon



Managing Director
at
Versant Venture Management, LLC


Location: Menlo Park, CA





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Brad Bolzon



Managing Director
at
Versant Venture Management, LLC


Location: Menlo Park, CA




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Brad Bolzon is both a Menlo Park and Basel, Switzerland-based Managing Director.
Brad brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.
Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.



5

Companies in Career





N/A

Related Markets





N/A

Colleagues





1

Related Investments








Alias
N/A



Industry
Venture Capital




Tags
N/A




Topics of Influence












Web Site







N/A
























Careers








Achievements








Investments








Related People






 Edit
View all 



Brad BolzonCareer (5)











RuiYi



Board Member












Versant Venture Management, LLC



Managing Director












Euroventures Capital Advisory



Board Member












Flexion Therapeutics



Board Member












Biotie Therapies



Board Member








Competencies










 Edit
View all 



Brad BolzonEducation (2)










University of Toronto













University of Toronto












 Edit



Brad BolzonAchievements and Recognitions





Add Milestone


No milestones has been recorded for Brad Bolzon






 Edit



Brad BolzonLinks





Add Link


No links has been recorded for Brad Bolzon









Brad BolzonInvestments/Acquisitions





No investments has been recorded for Brad Bolzon






View all 



Brad BolzonInvestments Representing Others









lead
Crispr Therapeutics

Representing: Versant Ventures



Since Apr-2014


Series: A, A, B

Company status: PUBLIC










Brad BolzonRelated People





No colleagues and peers has been recorded for Brad Bolzon








View all 



Brad BolzonRecommended Market Profiles (8)








Telemedicine

10,000 or More employees
19 companies








Social Media Marketing (ChiefMartec.com)

5,000 - 10,000 employees
111 companies








Big Data Universe List of Lists

10,000 or More employees
533 companies








Aggregated Marketing Technology

10,000 or More employees
2650 companies








Shared Economy Landscape (Jeremiah Owyang)

10,000 or More employees
267 companies








Inside Sales Landscape

10,000 or More employees
650 companies























Home - Versant Ventures


































Search for:



 



Versant Ventures on LinkedIn

 

Share

LP Access
Contact Us
Careers














I've built two companies with Versant Ventures and value their distinctive investment approach. They have a clear understanding of the recipe for start-up company success and represent a premium brand in healthcare venture capital today.
David Clapper
 / Minerva Surgical
Versant. Invested in Life.





The people at Versant understand the entrepreneurial process. They take a long-term view of the portfolio company, and help provide perspective and support in times thick and thin.
Amar Sawhney
 / Ocular Therapeutix
Versant. Invested in Life.





Versant has been and continues to be a superb investor. They provide insight and counsel to our efforts and their willingness to roll up their sleeves to problem solve with us has been invaluable.
Michael D. Clayman, MD
 / Flexion Therapeutics
Versant. Invested in Life.











 


Featured Case Study




BIOTECHNOLOGY
Quanticel Pharmaceuticals
Quanticel technology is based on the work of Stanford researchers and company founders Stephen Quake and Michael Clarke. Versant had backed other genomic technologies invented by Quake, and moved quickly to incubate Quanticel in 2010, shortly after the company was founded.

The idea behind Quanticel’s single-cell genomic analysis technology is to unlock the mystery of cancer drug resistance through the analysis of tumor cell heterogeneity. As a tumor grows and cancer cells rapidly replicate, the genetic diversity of these cells increases...
Full Quanticel Pharmaceuticals Case Study








News Highlights

VenatoRx Pharmaceuticals Raises $42 Million Series B 
VenatoRxfinal 


Repare Therapeutics Raises $US68 Million Series A 
Repare Therapeutics Raises US$68 Million Series A 


CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation 
CRISPR appoints Jon Terrett 


Versant Ventures Launches Jecure Therapeutics 
jecure-series-a 
























Versant Venture Management LLC | Company Profile from Hoover’s - D&B Hoovers








































































Menu









Buy Reports & Lists
How It Works




United States
United Kingdom



(855) 891-0791


Login
















Company
People
Industry





Search D&B Hoovers: Company | People | Industry








Login





Avention OneSource is now D&B Hoovers. Login here for access to D&B Hoovers, D&B DataVision, D&B Business Browser and iSell
Login







For customers of Hoovers prior to March 1, 2017.
Login




















Call (866) 473-3932





Chat software by BoldChat



Start Free Trial








Call (866) 473-3932





Chat software by BoldChat



Start Free Trial




















Search the D&B Hoovers Database

Company

Company
People
Industry

















Home
                >Company Information
                >Company Search
                >Company Overview - Profile


















Company Profile


Information For


Sales Preparation


Marketing Contacts


Competition


Revenue & Financial


Available Products


Company Report


Finance and Insurance Sector Industry Report


Investment Firms Industry Report


Venture Capital Industry Report


















Versant Venture Management LLCCompany Information

1 Sansome St Ste 3630San Francisco, CA, 94104 United States(650) 233-7877 †
http://www.versantventures.com
Top 3 Competitors

NEW ENTERPRISE ASSOCIATES, INC.
FRAZIER MANAGEMENT LLC
Healthcare Ventures LLC



Unlock more access to Hoover’s!

Build customized email lists 24/7, based on your best customer profile.
Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day. 
Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile. 


Request Your Free Trial

Call (866) 473-3932 today to get started with a FREE TRIAL!
 



 

Versant Venture Management LLC Company Profile

   Versant Venture is conversant in the world of health care startups. Doing business as Versant Ventures, the firm primarily invests in early-state health care and biotech companies including medical device makers, service providers, pharmaceuticals, and IT firms. It targets companies with potential sales of more than $500 million. Versant manages more than $1.6 billion in committed capital in some 75 portfolio firms. Holdings include include Fluidigm, Cogent Healthcare, and Metabolex. A group of managing directors including Samuel Colella co-founded Versant Ventures in 1999.
  
† Some telephone numbers on the Hoover’s site may be on a country’s do not call or do not contact list including, but not limited to, the United Kingdom’s CTPS or TPS registers. It is a legal requirement that companies do not make sales or marketing calls to registered numbers. These are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls. By using the information provided on the Hoover’s sites, as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local, state, national or international laws and regulations, including any local do not call registers or marketing regulations, and agree to defend, indemnify and hold harmless Dun & Bradstreet and each of its affiliates in the event your use violates such laws and regulations.

Additional Versant Venture Management LLC Information

Sales Preparation

Get relevant industry context to prepare for your next sales call – trends, competitors, news, call prep questions, and more.



Marketing Campaigns

Find prospect companies that meet the profile of your best customers to maximize campaign ROI.




Strategy & Planning

Identify new market opportunities and new strategies for existing markets.



Credit Management & Finance

Determine and track a company’s financial condition.




Related Tags

San Francisco, CA, United States
Finance & Insurance Sector
Investment Firms
Venture Capital







































FREE Alerts to Changes in Your D&B® Credit Scores!* Sign Up.
Get CreditSignal® for FREE!*












Try D&B Credit FREE for 30 Days! Get Started.
Try D&B Credit FREE for 30 Days





















